1. Home >
  2. M&A >
  3. Divestiture >
  4. United States >
  5. California >
  6. Sandoz International Acquires Cimerli

M&A Deal Summary

Sandoz International Acquires Cimerli

On March 4, 2024, Sandoz International acquired life science company Cimerli from Coherus Biosciences for 170M USD

Acquisition Highlights
  • This is Sandoz International’s 4th transaction in the Life Science sector.
  • This is Sandoz International’s 4th largest (disclosed) transaction.
  • This is Sandoz International’s 2nd transaction in the United States.
  • This is Sandoz International’s 1st transaction in California.

M&A Deal Summary
Date 2024-03-04
Target Cimerli
Sector Life Science
Buyer(s) Sandoz International
Sellers(s) Coherus Biosciences
Deal Type Divestiture
Deal Value 170M USD

Target

Cimerli

Redwood City, California, United States
Cimerli is a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Myopic Choroidal Neovascularization (mCNV). Cimerli is based in Redwood City, California.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Sandoz International

Holzkirchen, Germany
Category Company
Sector Life Science
DESCRIPTION

Sandoz International GmbH is a developer, manufacturer and markets generic pharmaceutical products focused on biosimilars, injectables, inhalers and transdermal patches.

DEAL STATS #
Overall 5 of 5
Sector: Life Science M&A 4 of 4
Type: Divestiture M&A Deals 4 of 4
State: California M&A 1 of 1
Country: United States M&A 2 of 2
Year: 2024 M&A 1 of 1
Size (of disclosed) 4 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-02-11 GSK - Cephalosporin Antibiotics Business

Brentford, United Kingdom

GSK's Cephalosporin Antibiotics Business is a provider of antibiotics used to treat a range of bacterial infections.

Buy $500M

Seller(S) 1

SELLER

Coherus Biosciences

Redwood City, California, United States
Category Company
Founded 2010
Sector Life Science
Employees228
Revenue 267M USD (2024)
DESCRIPTION

Coherus Biosciences is a biotechnology company focused on developing products. Coherus BioSciences was founded in 2010 and is based in Redwood City, California.

DEAL STATS #
Overall 1 of 2
Sector: Life Science M&A 1 of 2
Type: Divestiture M&A Deals 1 of 2
State: California M&A 1 of 2
Country: United States M&A 1 of 2
Year: 2024 M&A 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-06-16 Surface Oncology

Cambridge, Massachusetts, United States

Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned programs: SRF388, a Phase 2 program targeting IL-27, and SRF114, a Phase 1 program that selectively depletes regulatory T cells in the tumor microenvironment via targeting CCR8. Surface Oncology was founded in 2014 and is based in Cambridge, Massachusetts.

Buy $65M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2025-04-14 Udenyca

Redwood City, California, United States

Udenyca (pegfilgrastim-cbqv) is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. It increases survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).

Sell -
Mergr

Solution for

Product

Company

Legal